Browsing by Author "Maurer-Stroh, Sebastian"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
- Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020Publication . Alm, Erik; Broberg, Eeva K; Connor, Thomas; Hodcroft, Emma B; Komissarov, Andrey B; Maurer-Stroh, Sebastian; Melidou, Angeliki; Neher, Richard A; O’Toole, Áine; Pereyaslov, Dmitriy; WHO European Region sequencing laboratories and GISAID EpiCoV group; WHO European Region sequencing laboratories and GISAID EpiCoV groupWe show the distribution of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genetic clades over time and between countries and outline potential genomic surveillance objectives. We applied three genomic nomenclature systems to all sequence data from the World Health Organization European Region available until 10 July 2020. We highlight the importance of real-time sequencing and data dissemination in a pandemic situation, compare the nomenclatures and lay a foundation for future European genomic surveillance of SARS-CoV-2.
- Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015Publication . Hurt, Aeron C.; Besselaar, Terry G.; Daniels, Rod S.; Ermetal, Burcu; Fry, Alicia; Gubareva, Larisa; Huang, Weijuan; Lackenby, Angie; Lee, Raphael T.C.; Lo, Janice; Maurer-Stroh, Sebastian; Nguyen, Ha T.; Pereyaslov, Dmitriy; Rebelo-de-Andrade, Helena; Siqueira, Marilda M.; Takashita, Emi; Tashiro, Masato; Tilmanis, Danielle; Wang, Dayan; Zhang, Wenqing; Meijer, AdamThe World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza (WHO CCs) tested 13,312 viruses collected by WHO recognized National Influenza Centres between May 2014 and May 2015 to determine 50% inhibitory concentration (IC50) data for neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. Ninety-four per cent of the viruses tested by the WHO CCs were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 0.5% (n = 68) of viruses showed either highly reduced inhibition (HRI) or reduced inhibition (RI) (n = 56) against at least one of the four NAIs. Of the twelve viruses with HRI, six were A(H1N1)pdm09 viruses, three were A(H3N2) viruses and three were B/Yamagata-lineage viruses. The overall frequency of viruses with RI or HRI by the NAIs was lower than that observed in 2013-14 (1.9%), but similar to the 2012-13 period (0.6%). Based on the current analysis, the NAIs remain an appropriate choice for the treatment and prophylaxis of influenza virus infections.
- Urgent need for a non-discriminatory and non-stigmatizing nomenclature for monkeypox virusPublication . Happi, Christian; Adetifa, Ifedayo; Mbala, Placide; Njouom, Richard; Nakoune, Emmanuel; Happi, Anise; Ndodo, Nnaemeka; Ayansola, Oyeronke; Mboowa, Gerald; Bedford, Trevor; Neher, Richard A.; Roemer, Cornelius; Hodcroft, Emma; Tegally, Houriiyah; O’Toole, Áine; Rambaut, Andrew; Pybus, Oliver; Kraemer, Moritz U. G.; Wilkinson, Eduan; Isidro, Joana; Borges, Vítor; Pinto, Miguel; Gomes, João Paulo; Freitas, Lucas; Resende, Paola C.; Lee, Raphael T. C.; Maurer-Stroh, Sebastian; Baxter, Cheryl; Lessells, Richard; Ogwell, Ahmed E.; Kebede, Yenew; Tessema, Sofonias K.; de Oliveira, TulioWe propose a novel, non-discriminatory classification of monkeypox virus diversity. Together with the World Health Organization, we named three clades (I, IIa and IIb) in order of detection. Within IIb, the cause of the current global outbreak, we identified multiple lineages (A.1, A.2, A.1.1 and B.1) to support real-time genomic surveillance.